TARDBP and amyotrophic lateral sclerosis: EPZ-6438 (Tazemetostat), an inhibitor of the enhancer of zeste homolog 2 (EZH2) responsible for H3K27 methylation, was found to reduce DNA damage in MN derived from a C9-ALS-iPSC line, but failed to correct TDP-43 subcellular mislocalization [124].